CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

cancer immunotherapy
Boosting CAR T Cell Therapy for Solid Tumors
Boosting CAR T Cell Therapy for Solid Tumors
The Scientist Creative Services Team in Collaboration with IsoPlexis | Apr 5, 2021
Katie McKenna will discuss how oncolytic viral therapy enhances CAR-T cell killing of cancer cells.
Fecal Transplant Could Boost Immunotherapy to Treat Melanoma
Fecal Transplant Could Boost Immunotherapy to Treat Melanoma
Shawna Williams | Feb 12, 2021
The results from two Phase 1 trials bolster the case that the gut microbiome plays a role in response to the drugs.
The Scientist Speaks Podcast - Episode 10
The Scientist Speaks Podcast - Episode 10
The Scientist Creative Services Team | Oct 28, 2020
Cancer Immunotherapy: CRISPR Reveals Targets In Vivo
The Scientist's LabTalk Podcast - Episode 1
The Scientist's LabTalk Podcast - Episode 1
The Scientist Creative Services Team | Sep 11, 2020
Myeloid Cells in Cancer and Science Advocacy: A Conversation with Dr. Miriam Merad
Immunotherapy Combo Reduces Solid Tumors in Mice
Immunotherapy Combo Reduces Solid Tumors in Mice
Amanda Heidt | Sep 9, 2020
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
Adoptive Cell Therapy Summit
Adoptive Cell Therapy Summit
The Scientist Creative Services Team | Aug 24, 2020
Join us to learn about adoptive cell therapies from leading experts in the field of cancer immunology. 
Contributors
Contributors
The Scientist Staff | Jul 13, 2020
Meet some of the people featured in the July/August 2020 issue of The Scientist.
Harnessing Stem Cell–Like T Cells to Better Fight Cancer
Harnessing Stem Cell–Like T Cells to Better Fight Cancer
Daniel E. Speiser and Werner Held | Jul 13, 2020
Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.
Natural Killer Cell Therapies Catch Up to CAR T
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020
There’s a new cell-based cancer immunotherapy on the block.
Flu Shot Ignites Immune Attack Against Cancer in Mice
Flu Shot Ignites Immune Attack Against Cancer in Mice
Ashley Yeager | Apr 1, 2020
Injecting the seasonal flu vaccine directly into clumps of malignant cells recruits immune cells to confront the cancer.
Novel DNA-Sensing Pathway Found in Human Cells, Absent in Mice
Novel DNA-Sensing Pathway Found in Human Cells, Absent in Mice
Catherine Offord | Jan 24, 2020
This previously unknown mechanism for spotting foreign genetic material in the cytoplasm launches antiviral defenses even when the well-known immune mediator STING is absent.
Immunology Leader Vincenzo Cerundolo Dies
Immunology Leader Vincenzo Cerundolo Dies
Ashley Yeager | Jan 16, 2020
The Oxford researcher’s work on lipid and peptide antigens revealed key mechanisms in inflammation, immunotherapy, and vaccination, which are being pursued in clinical trial treatments.
Does the Microbiome Help the Body Fight Cancer?
Does the Microbiome Help the Body Fight Cancer?
Catherine Offord | Jul 10, 2019
Research in mice and humans is beginning to establish a link between the composition of microbes in the gut and immune responses to tumor cells, but the mechanisms are not yet clear.
Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
Shawna Williams | Apr 16, 2019
One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.
Tuberculosis Can Emerge After Cancer Immunotherapy
Tuberculosis Can Emerge After Cancer Immunotherapy
Ashley Yeager | Apr 1, 2019
At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
Kerry Grens | Apr 1, 2019
The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Kerry Grens | Apr 1, 2019
Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.
More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes
Catherine Offord | Jan 15, 2019
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.